{"id":745025,"date":"2014-03-04T17:30:00","date_gmt":"2014-03-04T17:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\/"},"modified":"2023-03-22T00:04:58","modified_gmt":"2023-03-22T04:04:58","slug":"merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\/","title":{"rendered":"Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet"},"content":{"rendered":"<p class=\"bwalignc\">       Data Presented at the 2014 Annual Meeting of the American Academy of        Allergy, Asthma &amp; Immunology (AAAAI)     <\/p>\n<p>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced results from a Phase 2b study evaluating two doses of<br \/>\n      its investigational house dust mite sublingual immunotherapy tablet<br \/>\n      (MK-8237). The data were presented for the first time during a<br \/>\n      late-breaking oral session at the 2014 Annual Meeting of the American<br \/>\n      Academy of Allergy, Asthma &amp; Immunology (AAAAI) in San Diego.\n    <\/p>\n<p>\n      The study was conducted in 124 adult patients 18 years of age and older<br \/>\n      with house dust mite-induced allergic rhinitis, with or without<br \/>\n      conjunctivitis, using an environmental exposure chamber. In the study,<br \/>\n      MK-8237 at once-daily doses of 6 Development Units (DU) and 12 DU<br \/>\n      produced a significant dose- and time-dependent reduction in average<br \/>\n      total nasal symptom score (TNSS) over the last four hours of the chamber<br \/>\n      challenge at week 24 of treatment compared to placebo (-27%=6 DU,<br \/>\n      -49%=12 DU; p&lt;0.05 for both vs. placebo), the primary efficacy endpoint<br \/>\n      of the study. TNSS is the total score for four nasal symptoms: itchy<br \/>\n      nose, blocked nose, runny nose and sneezing.\n    <\/p>\n<p>\n      \u201cMerck is committed to the research and development of sublingual tablet<br \/>\n      immunotherapy options for the treatment of allergic rhinitis,\u201d said Dr.<br \/>\n      Sean Curtis, vice president, Respiratory and Immunology, Merck Research<br \/>\n      Laboratories. \u201cWe look forward to continuing with Phase 3 research,<br \/>\n      which will provide further insight into the safety and efficacy of<br \/>\n      MK-8237.\u201d\n    <\/p>\n<p>\n      <b>Study Design<\/b>\n    <\/p>\n<p>\n      In this double-blind, single-site, Phase 2b study, 124 adults, 18 years<br \/>\n      of age or older, with house dust mite-induced allergic rhinitis, with or<br \/>\n      without conjunctivitis, were randomized to receive 6 DU (n=41) or 12 DU<br \/>\n      (n=42) of MK-8237 sublingual tablets once daily for 24 weeks or placebo<br \/>\n      (n=41). Sensitivity to house dust mite allergen was determined by<br \/>\n      specific IgE testing. Patients with unstable uncontrolled\/partially<br \/>\n      controlled or severe asthma were excluded from the study, as were<br \/>\n      patients with forced expiratory volume in 1 second (FEV<sub>1<\/sub>) &lt;70<br \/>\n      percent of predicted value. Participants were exposed to the house dust<br \/>\n      mite allergen using an environmental exposure chamber at weeks 8, 16 and<br \/>\n      24. This method allows for controlled and reproducible conditions that<br \/>\n      provide a constant concentration of allergen over a six-hour period with<br \/>\n      patients recording symptoms every 15 minutes.\n    <\/p>\n<p>\n      <b>Study Results<\/b>\n    <\/p>\n<p>\n      Both doses of MK-8237 showed a significant dose- and time-dependent<br \/>\n      reduction in average TNSS over the last four hours of the chamber<br \/>\n      challenge at week 24 of treatment compared to placebo (-27%=6 DU,<br \/>\n      -49%=12 DU; p&lt;0.05 for both vs. placebo). Key secondary efficacy<br \/>\n      endpoints of the study were average TNSS over the last four hours of the<br \/>\n      chamber challenge at weeks 8 and 16 compared to placebo, and average<br \/>\n      total symptom score (TSS) over the last four hours of the chamber<br \/>\n      challenge at week 24 compared to placebo. TSS is the total score for<br \/>\n      four nasal symptoms (itchy nose, blocked nose, runny nose and sneezing)<br \/>\n      and two ocular symptoms (gritty feeling\/red\/itchy eyes and watery eyes).<br \/>\n      MK-8237 demonstrated dose-dependent reductions versus placebo in average<br \/>\n      TNSS at week 8 (-8%=6 DU; p=NS and -20%=12 DU; p&lt;0.05) and at week 16<br \/>\n      (-18%=6 DU, -30%=12 DU; p&lt;0.05 for both vs. placebo). MK-8237 also<br \/>\n      demonstrated dose-dependent reductions versus placebo in average TSS at<br \/>\n      week 24 (-29%=6 DU, -52%=12 DU (p&lt;0.05 for both vs. placebo).\n    <\/p>\n<p>\n      In this study, the most common adverse events (incidence \u2265 5%) occurring<br \/>\n      in patients receiving MK-8237 6 DU, 12 DU or placebo, respectively, were<br \/>\n      throat irritation (34%, 52%, 0%), mouth edema (24%, 24%, 0%), lip<br \/>\n      swelling (5%, 17%, 2%), oral pruritus (15%, 14%, 0%), dyspepsia (2%,<br \/>\n      10%, 0%), ear pruritus (0%, 7%, 0%), swollen tongue (0%, 5%, 0%),<br \/>\n      oropharyngeal swelling (0%, 5%, 0%) and pharyngeal edema (2%, 5%, 0%).<br \/>\n      There were no local swellings of severe intensity and no serious adverse<br \/>\n      events reported in patients treated with MK-8237. The majority of<br \/>\n      adverse events in this study were assessed as mild or moderate. There<br \/>\n      were no investigator reported systemic allergic reactions or reactions<br \/>\n      treated with epinephrine for either dose of MK-8237.\n    <\/p>\n<p>\n      A Phase 3 study of MK-8237 in adolescents and adults with house dust<br \/>\n      mite-induced allergic rhinitis is currently screening patients. Details<br \/>\n      of the study can be viewed on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov%2Fct2%2Fshow%2FNCT01700192%3Fterm%3DMK-8237%26rank%3D2&amp;esheet=50817124&amp;newsitemid=20140304006818&amp;lan=en-US&amp;anchor=ClinicalTrials.gov&amp;index=1&amp;md5=276d93c28babd14dca1a5eca25d793a2\" rel=\"nofollow\">ClinicalTrials.gov<\/a>.\n    <\/p>\n<p>\n      <b>Additional Merck Research Presented at AAAAI<\/b>\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        Efficacy of the Short-Ragweed Sublingual Immunotherapy Tablet MK-3641<br \/>\n        in Monosensitized and Polysensitized Subjects (Poster 756);\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        The Effect of the Ragweed Sublingual Immunotherapy Tablet MK-3641 on<br \/>\n        Rescue Medication Use (Poster 972);\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        The Efficacy and Safety of the Short-Ragweed Sublingual Immunotherapy<br \/>\n        Tablet MK-3641 is Similar in Asthmatic and Nonasthmatic Subjects<br \/>\n        Treated for Allergic Rhinitis with\/without Conjunctivitis (AR\/C)<br \/>\n        (Poster 754);\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        Magnitude of Changes in Patient Symptom and Medication Scores in Grass<br \/>\n        Allergy Immunotherapy Trials: Dependency on Levels of Pollen Exposure<br \/>\n        (Poster 767).\n      <\/li>\n<\/ul>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=50817124&amp;newsitemid=20140304006818&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=7a67a36d65a845931b4c91587a77d645\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=50817124&amp;newsitemid=20140304006818&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=543b94bc024ef835249f675ec3708999\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=50817124&amp;newsitemid=20140304006818&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=6c860b172fbf17333abdb82869a1baed\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=50817124&amp;newsitemid=20140304006818&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=058f625ab19bc7e2c8b501b4438c2985\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2013 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=50817124&amp;newsitemid=20140304006818&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=fd6092f2fc558fa5b2f93b6ba9e2e9b4\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140304006818r1&amp;sid=hq1sf1&amp;distro=nx\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pam Eisele, 267-305-3558<br \/>or<br \/>Robert        Consalvo, 908-423-6595<br \/>or<br \/>Investor:<br \/>Carol Ferguson,        908-423-4465<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Data Presented at the 2014 Annual Meeting of the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting of the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) in San Diego. The study was conducted in 124 adult patients 18 years of age and older with house dust mite-induced allergic rhinitis, with or without conjunctivitis, using an environmental exposure chamber. In the study, MK-8237 at once-daily doses of 6 Development Units (DU) and 12 DU produced a significant dose- and time-dependent reduction in average total nasal symptom score (TNSS) over the last four hours of the chamber challenge at week 24 of treatment compared to placebo (-27%=6 DU,<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[64,289,56],"class_list":["post-745025","news_item","type-news_item","status-publish","hentry","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Data Presented at the 2014 Annual Meeting of the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting of the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) in San Diego. The study was conducted in 124 adult patients 18 years of age and older with house dust mite-induced allergic rhinitis, with or without conjunctivitis, using an environmental exposure chamber. In the study, MK-8237 at once-daily doses of 6 Development Units (DU) and 12 DU produced a significant dose- and time-dependent reduction in average total nasal symptom score (TNSS) over the last four hours of the chamber challenge at week 24 of treatment compared to placebo (-27%=6 DU,\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:58+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140304006818r1&amp;sid=hq1sf1&amp;distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\\\/\",\"name\":\"Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140304006818r1&amp;sid=hq1sf1&amp;distro=nx\",\"datePublished\":\"2014-03-04T17:30:00+00:00\",\"dateModified\":\"2023-03-22T04:04:58+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140304006818r1&amp;sid=hq1sf1&amp;distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20140304006818r1&amp;sid=hq1sf1&amp;distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\/","og_locale":"en_US","og_type":"article","og_title":"Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet - Merck.com","og_description":"Data Presented at the 2014 Annual Meeting of the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from a Phase 2b study evaluating two doses of its investigational house dust mite sublingual immunotherapy tablet (MK-8237). The data were presented for the first time during a late-breaking oral session at the 2014 Annual Meeting of the American Academy of Allergy, Asthma &amp; Immunology (AAAAI) in San Diego. The study was conducted in 124 adult patients 18 years of age and older with house dust mite-induced allergic rhinitis, with or without conjunctivitis, using an environmental exposure chamber. In the study, MK-8237 at once-daily doses of 6 Development Units (DU) and 12 DU produced a significant dose- and time-dependent reduction in average total nasal symptom score (TNSS) over the last four hours of the chamber challenge at week 24 of treatment compared to placebo (-27%=6 DU,","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:58+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140304006818r1&amp;sid=hq1sf1&amp;distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\/","name":"Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140304006818r1&amp;sid=hq1sf1&amp;distro=nx","datePublished":"2014-03-04T17:30:00+00:00","dateModified":"2023-03-22T04:04:58+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140304006818r1&amp;sid=hq1sf1&amp;distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20140304006818r1&amp;sid=hq1sf1&amp;distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-announces-results-from-phase-2b-study-of-mk-8237-an-investigational-house-dust-mite-sublingual-allergen-immunotherapy-tablet\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Announces Results from Phase 2b Study of MK-8237, an Investigational House Dust Mite Sublingual Allergen Immunotherapy Tablet"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"d28146eb-84f7-4395-aa41-06234c93c185","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-Announces-Results-from-Phase-2b-Study-of-MK-8237-an-Investigational-House-Dust-Mite-Sublingual-Allergen-Immunotherapy-Tablet-2014.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745025","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745025\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745025"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745025"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}